Development of the 2017 BIO International Convention’s robust education program is well underway and promises to live up to this year’s theme: “Breakthrough.” Eighteen separate tracks, along with Super Sessions, Fireside Chats and Keynotes, will highlight the biotech industry’s many breakthrough innovations, challenges and prospects for the future.
Consider the Fireside Chat with Kate Rubins, the first person to sequence DNA in space! Ms. Rubins will discuss her breakthrough experience of spending 115 days beyond Earth’s atmosphere, where she conducted two spacewalks and other experiments. In addition to her experience as an astronaut, Ms. Rubins, holds a PhD in Cancer Biology and has studied infectious diseases affecting Africa. Her Fireside Chat will take place on Tuesday, June 21 from 3:00 – 4:00 PM.
On the international front, former United Kingdom (UK) Prime Minister, David Cameron, will be a keynote speaker. When voters in the UK approved a referendum to leave the European Union, a transformative new period for geopolitics and international business began. During an interview with Jim Greenwood, BIO’s President and Chief Executive Officer, Cameron will offer his insights about how the biotechnology industry can navigate the new political climate to expand innovation and serve a global customer base during a time when some of the world’s leading economies are looking inward. The session is sponsored by Johnson & Johnson Innovation.
Be sure to review the many educational tracks that will explore the breakthroughs that are making headlines and driving the biotech industry to new heights, innovations and life-saving therapies. For example,
Oncology: Racing to create a new generation of cancer killers
Learn how companies are facing the challenges of staying relevant in the fast paced, cancer R&D ecosystem including exploring the exciting potential or CAR-T therapies, the promise of combination therapies for cancer research and whether immune-oncology drugs could supplant tumoricidal drugs and radiation as first line therapy for most cancers.
Digital Health: Enhancing the speed, quality and cost of health care
Review the growth of digital health and its implications for disrupting or integrating healthcare over the next decade. Digital health technology is enabling a fundamental shift in the value chain from applications in personal genomics, detection technology and artificial intelligence to investments in the biotech sector.
Big Data – Driving Innovation in Biomedicine: Harnessing the value of Big Data
Analyze creating an infrastructure to translate the data tsunami into actionable knowledge for researchers, drug developers and clinicians.
Value, Patient Access, and Commercialization: Rethinking the drug ecosystem
Examine the entire value chain for drugs from Outcome Based Contracting (OBCs) to patient perspectives on value assessment frameworks and much more.
BIO 2017 will be held in San Diego, home to a rich cluster of genomics and precision medicine experts and other life science companies. Registration is now open and a discounted rate is in effect until April 27.
Complimentary media registration is open and available to qualified reporters working full time for print, broadcast, and web publications with valid press credentials.